Published in Schizophr Bull on May 08, 2009
Mobile Assessment and Treatment for Schizophrenia (MATS): a pilot trial of an interactive text-messaging intervention for medication adherence, socialization, and auditory hallucinations. Schizophr Bull (2011) 2.58
Smartphone ownership and interest in mobile applications to monitor symptoms of mental health conditions. JMIR Mhealth Uhealth (2014) 1.74
Mobile assessment guide for research in schizophrenia and severe mental disorders. Schizophr Bull (2012) 1.30
New Tools for New Research in Psychiatry: A Scalable and Customizable Platform to Empower Data Driven Smartphone Research. JMIR Ment Health (2016) 1.08
Heart rate variability in bipolar mania and schizophrenia. J Psychiatr Res (2009) 1.03
The association of cardiac vagal control and executive functioning--findings from the MIDUS study. J Psychiatr Res (2013) 0.88
Abuse-related post-traumatic stress, coping, and tobacco use in pregnancy. J Obstet Gynecol Neonatal Nurs (2011) 0.83
Emotional granularity and social functioning in individuals with schizophrenia: an experience sampling study. J Psychiatr Res (2014) 0.82
Predictors of Self-Stigma in Schizophrenia: New Insights Using Mobile Technologies. J Dual Diagn (2012) 0.82
Advantages and psychometric validation of proximal intensive assessments of patient-reported outcomes collected in daily life. Qual Life Res (2015) 0.78
Depressed mood in individuals with schizophrenia: A comparison of retrospective and real-time measures. Psychiatry Res (2015) 0.78
Use of mobile assessment technologies in inpatient psychiatric settings. Asian J Psychiatr (2014) 0.77
The Promises and Challenges of Ecological Momentary Assessment in Schizophrenia: Development of an Initial Experimental Protocol. Healthcare (Basel) (2015) 0.76
Autonomic Regulation and Auditory Hallucinations in Individuals With Schizophrenia: An Experience Sampling Study. Schizophr Bull (2017) 0.75
Longitudinal data analysis for discrete and continuous outcomes. Biometrics (1986) 60.93
Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation (1996) 37.54
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes (2006) 26.32
Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research. Psychol Bull (2004) 13.46
Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry (1994) 11.85
Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry (2003) 9.05
The neurobiology of stress: from serendipity to clinical relevance. Brain Res (2000) 4.51
Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry (1999) 3.69
Vulnerability--a new view of schizophrenia. J Abnorm Psychol (1977) 3.22
Emotional reactivity to daily life stress in psychosis. Arch Gen Psychiatry (2001) 2.20
Feasibility and validity of computerized ecological momentary assessment in schizophrenia. Schizophr Bull (2007) 2.12
The effects of perceived stress, traits, mood states, and stressful daily events on salivary cortisol. Psychosom Med (1997) 2.12
Computerized experience sampling method (ESMc): assessing feasibility and validity among individuals with schizophrenia. J Psychiatr Res (2005) 2.06
The effects of emotions on short-term power spectrum analysis of heart rate variability . Am J Cardiol (1995) 1.80
Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms. Neuropsychol Rev (2003) 1.71
Behavioral activation and inhibition in everyday life. J Pers Soc Psychol (2000) 1.57
Determinants of occurrence and recovery from hallucinations in daily life. Soc Psychiatry Psychiatr Epidemiol (2002) 1.53
Heart rate variability, trait anxiety, and perceived stress among physically fit men and women. Int J Psychophysiol (2000) 1.41
Effect of chronic stress associated with unemployment on salivary cortisol: overall cortisol levels, diurnal rhythm, and acute stress reactivity. Psychosom Med (1996) 1.35
Stressful life events and schizophrenia. I: A review of the research. Br J Psychiatry (1993) 1.26
Effect of mental stress throughout the day on cardiac autonomic control. Biol Psychol (1994) 1.22
The influence of psychotic states on the autonomic nervous system in schizophrenia. Int J Psychophysiol (1999) 1.20
Use of Palm computer as an adjunct to cognitive-behavioural therapy with an ultra-high-risk patient: a case report. Early Interv Psychiatry (2008) 1.17
Non-linear complexity measures of heart rate variability in acute schizophrenia. Clin Neurophysiol (2007) 1.17
A momentary assessment study of the relationship between affective and adrenocortical stress responses in daily life. Biol Psychol (2006) 1.14
Vagal rebound and recovery from psychological stress. Psychosom Med (2001) 1.12
Cortisol responses to daily events in major depressive disorder. Psychosom Med (2003) 1.11
Nonlinear complexity and spectral analyses of heart rate variability in medicated and unmedicated patients with schizophrenia. Neuropsychobiology (2004) 1.11
Loss of efferent vagal activity in acute schizophrenia. J Psychiatr Res (2005) 1.09
Heart rate variability in acute psychosis. Psychophysiology (2003) 1.06
Stress and psychosis: towards the development of new models of investigation. Clin Psychol Rev (2006) 1.04
Relationship between cardiovagal modulation and psychotic state in patients with paranoid schizophrenia. Psychiatry Res (2007) 0.99
Influences of an anticholinergic antiparkinsonian drug, parkinsonism, and psychotic symptoms on cardiac autonomic function in schizophrenia. J Clin Psychopharmacol (2003) 0.93
Altered diurnal autonomic variation and reduced vagal information flow in acute schizophrenia. Clin Neurophysiol (2006) 0.91
Heart rate dynamics and their relationship to psychotic symptom severity in clozapine-treated schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.90
Stress in schizophrenia: an integrative view. Eur J Pharmacol (2000) 0.90
Stressful life events and schizophrenia. II: Conceptual and methodological issues. Br J Psychiatry (1993) 0.89
Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia. J Psychopharmacol (2008) 0.86
A prospective study of daily stressors and symptomatology in schizophrenic patients. Soc Psychiatry Psychiatr Epidemiol (1994) 0.85
Low heart rate variability is not caused by typical neuroleptics in schizophrenia patients. CNS Spectr (2002) 0.85
Response variability of salivary cortisol under psychological stimulation. J Clin Chem Clin Biochem (1989) 0.82
Patterns of recovery of autonomic dysfunctions and neurocognitive deficits in schizophrenics after acute psychotic episodes. J Abnorm Psychol (2001) 0.80
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension (2006) 8.72
Inadequate sleep as a risk factor for obesity: analyses of the NHANES I. Sleep (2005) 8.15
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet (2003) 6.63
Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry (2004) 6.40
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry (2002) 5.14
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry (2005) 4.28
Boundary and medial shape analysis of the hippocampus in schizophrenia. Med Image Anal (2004) 4.25
Sleep duration as a risk factor for diabetes incidence in a large U.S. sample. Sleep (2007) 4.14
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry (2006) 3.66
Advancing paternal age and autism. Arch Gen Psychiatry (2006) 3.58
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry (2011) 3.49
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry (2008) 3.48
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry (2006) 3.28
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 3.21
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res (2005) 2.91
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry (2008) 2.86
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. Proc Natl Acad Sci U S A (2005) 2.73
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain. J Neurosci (2007) 2.61
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry (2002) 2.52
Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 2.38
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron (2013) 2.32
Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry (2009) 2.25
A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry (2006) 2.23
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 2.22
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry (2008) 2.10
Risk factors, confounding, and the illusion of statistical control. Psychosom Med (2004) 2.09
Computerized experience sampling method (ESMc): assessing feasibility and validity among individuals with schizophrenia. J Psychiatr Res (2005) 2.06
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res (2004) 2.06
Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in new york state. Psychiatr Serv (2009) 2.05
Teaching trainees to negotiate research collaborations with industry: a mentorship model. Am J Psychiatry (2010) 2.04
Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry (2005) 2.03
Sleep duration and risk for hypertension in women: results from the nurses' health study. Am J Hypertens (2013) 2.03
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Sleep duration associated with mortality in elderly, but not middle-aged, adults in a large US sample. Sleep (2008) 1.98
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res (2008) 1.97
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry (2011) 1.87
Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology (2005) 1.83
Components and correlates of family burden in schizophrenia. Psychiatr Serv (2006) 1.81
Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry (2010) 1.81
Depression among older people in Europe: the EURODEP studies. World Psychiatry (2004) 1.80
Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med (2007) 1.80
Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia. Am J Psychiatry (2010) 1.79
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry (2003) 1.76
Transcriptional profiling of bone regeneration. Insight into the molecular complexity of wound repair. J Biol Chem (2002) 1.73
Catechol-O-methyltransferase (COMT) genotypes and working memory: associations with differing cognitive operations. Biol Psychiatry (2005) 1.71
Paternal age and risk of schizophrenia in adult offspring. Am J Psychiatry (2002) 1.69
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry (2005) 1.68
Effects of daily events on mood states in major depressive disorder. J Abnorm Psychol (2003) 1.67
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry (2005) 1.66
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry (2002) 1.66
Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry (2008) 1.62
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study. J Am Acad Child Adolesc Psychiatry (2012) 1.62
Short sleep duration as a risk factor for hypercholesterolemia: analyses of the National Longitudinal Study of Adolescent Health. Sleep (2010) 1.59
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry (2004) 1.58
Psychiatric assessment of aggressive patients: a violent attack on a resident. Am J Psychiatry (2010) 1.56
The stress cascade and schizophrenia: etiology and onset. Schizophr Bull (2003) 1.56
Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res (2004) 1.56
What CATIE found: results from the schizophrenia trial. Psychiatr Serv (2008) 1.55
Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophr Res (2009) 1.54
Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Arch Gen Psychiatry (2005) 1.52
Religious attendance as a predictor of survival in the EPESE cohorts. Int J Epidemiol (2005) 1.52
Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry. Am J Psychiatry (2008) 1.49
Clozapine as a first treatment for schizophrenia. Am J Psychiatry (2003) 1.49
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry (2008) 1.49
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry (2010) 1.49
Prodromal interventions for schizophrenia vulnerability: the risks of being "at risk". Schizophr Res (2005) 1.48
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res (2005) 1.48
Earlier parental set bedtimes as a protective factor against depression and suicidal ideation. Sleep (2010) 1.48
Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) (2008) 1.46
Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res (2002) 1.45
Catatonia in DSM-5. Schizophr Res (2013) 1.43
Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol (2006) 1.42
The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr Bull (2005) 1.42
Facial expressiveness in patients with schizophrenia compared to depressed patients and nonpatient comparison subjects. Am J Psychiatry (2005) 1.39
Our future is now. Am J Psychiatry (2014) 1.39
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology (2004) 1.38
Diurnal mood variation in major depressive disorder. Emotion (2006) 1.38
Depression is associated with increased mortality 10 years after coronary artery bypass surgery. Psychosom Med (2010) 1.38
Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin Psychol Rev (2010) 1.38
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res (2008) 1.37
Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol Psychiatry (2003) 1.37
Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry (2008) 1.37